Adds details in paragraphs 2-3

July 22 (Reuters) - Johnson & Johnson JNJ.N said on Wednesday the U.S. Food and Drug Administration had granted marketing authorization for its robotic surgery device, clearing the way for the healthcare conglomerate to enter the soft-tissue robotic surgery market.

The Ottava robotic surgical system was authorized for use in multiple general surgery procedures in the upper abdomen, including gastric bypass, gastrectomy, gallbladder removal, gastric sleeve surgery, appendectomy and hiatal hernia repair.

J&J said it would begin a U.S. commercial launch with select customers, while working to expand the system into additional indications and regulatory markets.